メイン州における乳がんの臨床試験
メイン州内の拠点で、乳がんに関する16件の研究が参加者を募集しています。
メイン州内の都市
公式研究テキスト（英語）
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Harold Alfond Center for Cancer Care, Augusta
- MaineHealth Waldo Hospital, Belfast
- Lafayette Family Cancer Center-EMMC, Brewer
- 他9件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
- New England Cancer Specialists, Scarborough
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07102381A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- New England Cancer Specialists ( Site 0051), Westbrook
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06966700The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- The Jackson Laboratory (JAX) - Harold Alfond Center for Cancer Care, Augusta
- The Jackson Laboratory (JAX) - Northern Light Cancer Care, Brewer
被験者募集中第3相
60歳以上 · 全性別 · 2026/09/25更新 · NCT06377852Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Scarborough
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/23更新 · NCT07085767Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- New England Cancer Specialists, Westbrook
被験者募集中
18歳以上 · 全性別 · 2026/09/23更新 · NCT07214532A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- New England Cancer Specialists, Westbrook
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07174336ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- New England Cancer Specialists, Westbrook
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07173751A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- Barbara Ann Karmanos Cancer Institute, Detroit
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/08更新 · NCT07100106Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Harold Alfond Center for Cancer Care, Augusta
- MaineHealth Waldo Hospital, Belfast
- Mid Coast Hospital, Brunswick
- 他9件
被験者募集中第3相
18歳〜60歳 · 女性 · 2026/09/02更新 · NCT05879926ATEMPT 2.0: Adjuvant T-DM1 vs TH
- Eastern Maine Medical Center (Northern Light), Brewer
- New England Cancer Specialists, Scarborough
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/19更新 · NCT04893109Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
- Eastern Maine Medical Center, Brewer
被験者募集中第2相
18歳以上 · 全性別 · 2026/04/29更新 · NCT04468061De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- Lafayette Family Cancer Center-EMMC, Brewer
被験者募集中第3相
50歳〜70歳 · 全性別 · 2026/04/23更新 · NCT04852887Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Harold Alfond Center for Cancer Care, Augusta
- MaineHealth Waldo Hospital, Belfast
- MaineHealth Maine Medical Center - Biddeford, Biddeford
- 他7件
被験者募集中観察研究
18歳以上 · 全性別 · 2026/03/17更新 · NCT06418204SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Scarborough
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
- Northern Light Breast Care, Portland
被験者募集中観察研究
18歳以上 · 全性別 · 2025/08/20更新 · NCT03053193ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。